| Primary |
| Hypogammaglobulinaemia |
13.7% |
| Idiopathic Thrombocytopenic Purpura |
11.6% |
| Immunodeficiency Common Variable |
11.6% |
| Multiple Sclerosis |
9.5% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
8.4% |
| Dermatomyositis |
5.3% |
| Kawasaki's Disease |
4.2% |
| Myasthenia Gravis |
4.2% |
| Guillain-barre Syndrome |
3.2% |
| Hypoalbuminaemia |
3.2% |
| Paraproteinaemia |
3.2% |
| Pneumonia |
3.2% |
| Pneumonia Cytomegaloviral |
3.2% |
| Polymyositis |
3.2% |
| Bone Marrow Transplant |
2.1% |
| Hla Marker Study Positive |
2.1% |
| Neuropathy |
2.1% |
| Peripheral Sensory Neuropathy |
2.1% |
| Platelet Count Decreased |
2.1% |
| Premedication |
2.1% |
|
| Renal Failure Acute |
18.3% |
| Vomiting |
12.7% |
| Nausea |
8.5% |
| Pyrexia |
7.0% |
| Headache |
5.6% |
| Infusion Related Reaction |
5.6% |
| Renal Failure |
5.6% |
| Tremor |
5.6% |
| Chills |
4.2% |
| Meningitis Aseptic |
4.2% |
| Tachypnoea |
4.2% |
| Weight Increased |
4.2% |
| Hepatitis C Antibody Positive |
2.8% |
| Thrombotic Thrombocytopenic Purpura |
2.8% |
| Adverse Drug Reaction |
1.4% |
| Anaphylactic Reaction |
1.4% |
| Blood Creatinine Increased |
1.4% |
| Cardio-respiratory Arrest |
1.4% |
| Coagulopathy |
1.4% |
| Death |
1.4% |
|
| Secondary |
| Dermatomyositis |
17.4% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
15.2% |
| Guillain-barre Syndrome |
6.5% |
| Immunodeficiency Common Variable |
6.5% |
| Multiple Sclerosis |
6.5% |
| Product Used For Unknown Indication |
6.5% |
| Premedication |
5.4% |
| Primary Immunodeficiency Syndrome |
5.4% |
| Neuropathy |
4.3% |
| Paraproteinaemia |
4.3% |
| Autoimmune Disorder |
2.2% |
| Bone Marrow Transplant |
2.2% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Evans Syndrome |
2.2% |
| Kawasaki's Disease |
2.2% |
| Lumbosacral Plexus Injury |
2.2% |
| Lung Disorder |
2.2% |
| Lung Infection |
2.2% |
| Multi-organ Failure |
2.2% |
| Myasthenia Gravis |
2.2% |
|
| Liver Function Test Abnormal |
17.0% |
| Acute Respiratory Distress Syndrome |
10.6% |
| Tremor |
10.6% |
| Renal Failure |
8.5% |
| Myocardial Infarction |
6.4% |
| Headache |
4.3% |
| Infusion Related Reaction |
4.3% |
| Nausea |
4.3% |
| Off Label Use |
4.3% |
| Pain |
4.3% |
| Respiratory Distress |
4.3% |
| Vomiting |
4.3% |
| Drug Intolerance |
2.1% |
| Feeling Abnormal |
2.1% |
| Hepatitis |
2.1% |
| Hepatitis C Antibody Positive |
2.1% |
| Laboratory Test Abnormal |
2.1% |
| Oliguria |
2.1% |
| Pyrexia |
2.1% |
| Rash |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.7% |
| Immunodeficiency Common Variable |
8.3% |
| Mantle Cell Lymphoma |
8.3% |
| Pain |
8.3% |
| Thrombosis Prophylaxis |
8.3% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
4.2% |
| Dizziness |
4.2% |
| Hypertension |
4.2% |
| Hypothyroidism |
4.2% |
| Nausea |
4.2% |
| Selective Igg Subclass Deficiency |
4.2% |
|
| Pulmonary Embolism |
40.0% |
| Renal Failure |
20.0% |
| Tremor |
20.0% |
| Urticaria |
20.0% |
|
